First-line lenvatinib plus pembrolizumab treatment across non-clear cell renal cell carcinomas: Results of the phase 2 KEYNOTE-B61 study.

被引：0
|
作者：
Lee, Chung-Han
Gurney, Howard
Atduev, Vagif
Suarez, Cristina
Duran, Miguel A. Climent
Pook, David William
Tomczak, Piotr
Barthelemy, Philippe
Lee, Jae-Lyun
Nalbandian, Taron
Stus, Viktor
Ferguson, Thomas
Wiechno, Pawel
Gokmen, Erhan
Lacombe, Louis
Gedye, Craig
Burgents, Joseph
Sharma, Manish
Peng, Xiang
Albiges, Laurence
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] Macquarie Univ, Sydney, NSW, Australia
[3] Fed Med Biol Agcy, Volga Dist Med Ctr, Nizhnii Novgorod, Russia
[4] Hosp Univ Vall dHebron, Vall dHebron Inst Oncol VHIO, Med Oncol, Vall dHebron Barcelona Hosp Campus, Barcelona, Spain
[5] Inst Valenciano Oncol, Valencia, Spain
[6] Monash Hlth, Melbourne, Vic, Australia
[7] Poznan Univ Med Sci, Poznan, Poland
[8] Inst Cancerol Strasbourg Europe, Strasbourg, France
[9] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea
[10] Reg Canc Ctr, Kharkiv, Ukraine
[11] Dnipro State Med Univ, Dnipro, Ukraine
[12] Fiona Stanley Hosp, Perth, WA, Australia
[13] Inst Marii Sklodowskiej Curie, Oncol Ctr, Warsaw, Poland
[14] Ege Univ, Fac Med, Izmir, Turkiye
[15] CHU Quebec, Ctr Rech, Quebec City, PQ, Canada
[16] Univ Newcastle, Callaghan, NSW, Australia
[17] Merck & Co Inc, Rahway, NJ 07065 USA
[18] Gustave Roussy, Villejuif, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4518
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Anlotinib plus everolimus as first-line treatment for advanced non-clear cell renal cell carcinoma: A single-center, single-arm, phase II trial
    Zhang, Hailiang
    Ye, Dingwei
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [32] Final results of a phase II study of pembrolizumab as first-line treatment in advanced cutaneous squamous cell carcinomas (CSCCs)
    Maubec, E.
    Boubaya, M.
    Deschamps, L.
    Beylot-Barry, M.
    Petrow, P.
    Scheer-Senyarich, I.
    Basset-Seguin, N.
    Marqueste, C. Gaudy
    Quereux, G.
    Bloch-Queyrat, C.
    Leccia, M-T.
    Stefan, A.
    Saiag, P.
    Grange, F.
    Meyer, N.
    Rat, S. Dalac
    Alloux, C.
    Lopez, I.
    Tibi, A.
    Levy, V.
    ANNALS OF ONCOLOGY, 2023, 34 : S682 - S683
  • [33] Nivolumab plus cabozantinib in patients with non-clear cell renal cell carcinoma: Results of a phase 2 trial.
    Lee, Chung-Han
    Voss, Martin H.
    Carlo, Maria Isabel
    Chen, Ying-Bei
    Reznik, Eduard
    Knezevic, Andrea
    Lefkowitz, Robert A.
    Shapnik, Natalie
    Tassone, Diana
    Dadoun, Chloe
    Shah, Neil J.
    Owens, Colette Ngozi
    McHugh, Deaglan Joseph
    Aggen, David Henry
    Laccetti, Andrew Leonard
    Kotecha, Ritesh
    Feldman, Darren R.
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [34] KEYNOTE-427 cohort A: Pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (ccRCC)
    Donskov, F.
    McDermott, D. F.
    Lee, J. L.
    Szczylik, C.
    Malik, J.
    Alekseev, B. Y.
    Larkin, J. M. G.
    Matveev, V. B.
    Gafanov, R. Airatovich
    Tomczak, P.
    Tykodi, S. S.
    Geertsen, P. F.
    Wiechno, P.
    Shin, S. J.
    Pouliot, F.
    Alonso Gordoa, T.
    Silverman, R. Kloss
    Perini, R. F.
    Schloss, C.
    Atkins, M. B.
    ANNALS OF ONCOLOGY, 2018, 29
  • [35] Effectiveness of first-line therapy in patients with advanced non-clear renal cell carcinoma (nccRCC).
    Laramee, Sophie
    Ghosh, Sunita
    Kollmannsberger, Christian K.
    Hansen, Aaron Richard
    Wood, Lori
    Soulieres, Denis
    Canil, Christina M.
    Saleh, Ramy
    Castonguay, Vincent
    Bjarnason, Georg A.
    Basappa, Naveen S.
    Breau, Rodney H.
    Heng, Daniel Yick Chin
    Pouliot, Frederic
    Kapoor, Anil
    Lalani, Aly-Khan A.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [36] First-line pembrolizumab (pembro) monotherapy in advanced clear cell renal cell carcinoma (ccRCC): Updated results for KEYNOTE-427 cohort A.
    Tykodi, Scott S.
    Donskov, Frede
    Lee, Jae-Lyun
    Szczylik, Cezary
    Malik, Jahangeer
    Alekseev, Boris Yakovlevich
    Larkin, James M. G.
    Matveev, Vsevolod Borisovich
    Gafanov, Rustem
    Tomczak, Piotr
    Geertsen, Poul F.
    Wiechno, Pawel J.
    Shin, Sang Joon
    Pouliot, Frederic
    Alonso-Gordoa, Teresa
    Silverman, Rachel Kloss
    Perini, Rodolfo F.
    Schloss, Charles
    McDermott, David F.
    Atkins, Michael B.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [37] Editorial Comment on "Efficacy of pembrolizumab plus lenvatinib as first-line treatment for metastatic renal cell carcinoma with multiple brain metastases"
    Kato, Manabu
    IJU CASE REPORTS, 2025, 8 (01) : 9 - 10
  • [38] Real-world outcomes of first-line tislelizumab plus axitinib in patients with metastatic non-clear cell renal cell carcinoma (mnccRCC)
    Huang, T.
    Jiang, L.
    Wei, W.
    Zheng, X.
    Zhang, Z.
    Guo, S.
    Han, H.
    Cai, X.
    Zhou, F.
    Dong, P.
    ANNALS OF ONCOLOGY, 2023, 34 : S1559 - S1560
  • [39] Lenvatinib plus pembrolizumab as first-line therapy in patients with advanced renal cell carcinoma outside of clinical trials - results of a monocentric analysis
    Wullenkord, R.
    Heller, M.
    Ferber, D. S.
    Hoeper, C.
    Bochtler, T.
    Haag, G. M.
    Berger, A. K.
    Jaeger, D.
    Zschaebitz, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 320 - 321
  • [40] A phase 2 trial of lenvatinib in combination with everolimus in patients with advanced or metastatic non-clear cell renal cell carcinoma
    Hutson, Thomas
    Xing, Dongyuan
    Dutcus, Corina
    Baig, Mahadi
    Fishman, Mayer
    BJU INTERNATIONAL, 2016, 118 : 14 - 15
12345